Dr Stefan Leucht

MD, assistant professor, Department of Psychiatry, Technische Universität University Hospital, Munich, Germany.

Dr Leucht's special interests include pharmacogenetics and the treatment of schizophrenia. He has published several important meta-analyses about various pharmacological and psychotherapeutic treatments of schizophrenia. Since 1999 he has been a member of the editorial group of the Cochrane Schizophrenia Group.

---

Contributions to CNSforum by Dr Stefan Leucht:

31.05.2007

Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia

30.04.2007

Anticholinergic use in hospitalised schizophrenic patients in Belgium.

30.03.2007

Early Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia

28.02.2007

The use of electronic monitoring (MEMS(R)) to evaluate antipsychotic compliance in outpatients with schizophrenia

24.11.2006

Validation of remission criteria for schizophrenia

26.10.2006

Neurocognitive functioning in patients with first-episode schizophrenia : Results of a prospective 5-year follow-up study

30.09.2006

Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study

24.08.2006

Haloperidol Dose When Used as Active Comparator in Randomized Controlled Trials With Atypical Antipsychotics in Schizophrenia: Comparison With Officially Recommended Doses

25.07.2006

Outcomes of an effectiveness trial of cognitive-behavioural intervention by mental health nurses in schizophrenia

23.06.2006

Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey

23.05.2006

A national study of violent behavior in persons with schizophrenia

28.04.2006

Adverse Events During Medical and Surgical Hospitalizations for Persons With Schizophrenia

22.03.2006

Association of Schizophrenia and Autoimmune Diseases: Linkage of Danish National Registers

22.02.2006

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

17.01.2006

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

22.11.2005

Physical activity patterns in adults with severe mental illness

23.10.2005

Schizophrenia and cancer: an epidemiological study

28.09.2005

Schizophrenia practice guidelines: international survey and comparison

22.08.2005

A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

26.07.2005

Attitudes Toward Antipsychotic Medication. The Impact of Clinical Variables and Relationships With Health Professionals

16.06.2005

Mortality in Offspring of Parents With Psychotic Disorders: A Critical Review and Meta-Analysis

30.05.2005

A 4-Fold Risk of Metabolic Syndrome in Patients With Schizophrenia: The Northern Finland 1966 Birth Cohort Study

24.04.2005

The lifetime risk of suicide in schizophrenia: a reexamination

22.03.2005

Remission in schizophrenia: proposed criteria and rationale for consensus

28.02.2005

Predicting schizophrenia: findings from the Edinburgh High-Risk Study

31.01.2005

How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?

24.11.2004

Homicide and mental illness in New Zealand, 1970-2000

29.10.2004

Pleasurable auditory hallucinations

23.09.2004

Cognitive Enhancement Therapy for Schizophrenia. Effects of a 2-Year Randomized Trial on Cognition and Behavior

24.08.2004

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

28.06.2004

Risk for Cancer in Parents of Patients With Schizophrenia

24.05.2004

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

20.04.2004

Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia

24.03.2004

Symptomatic and Functional Recovery From a First Episode of Schizophrenia or Schizoaffective Disorder

25.02.2004

Causal association between cannabis and psychosis: examination of the evidence

28.01.2004

Schizophrenia as a Complex Trait. Evidence From a Meta-analysis of Twin Studies.

30.12.2003

Delayed-onset hypothesis of antipsychotic drug action. A hypothesis tested and rejected.

21.11.2003

Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial

27.10.2003

Compliance therapy: a randomised controlled trial in schizophrenia

30.09.2003

The schizoaffective phenomenon: the state of the art

30.08.2003

Reducing psychiatric stigma and discrimination: evaluation of educational interventions in UK secondary schools

29.07.2003

Parental Age and Risk of Schizophrenia: A Case-control Study

25.06.2003

Sex Differences in the Risk of Schizophrenia: Evidence From Meta-analysis.

26.05.2003

Insight in schizophrenia: a meta-analysis

30.04.2003

Reducing psychiatric stigma and discrimination: evaluation of educational interventions in UK secondary schools

30.03.2003

Association Between a Functional Catechol O-Methyltransferase Gene Polymorphism and Schizophrenia: Meta-Analysis of Case-Control and Family-Based Studies

24.02.2003

Subjective Experience and D2 Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study

29.01.2003

Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations

16.12.2002

Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study

22.11.2002

A highly significant association between a COMT haplotype and schizophrenia

21.10.2002

Duration of untreated psychosis and its correlates in first-episode psychosis in Finland and Spain

25.09.2002

Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms

19.08.2002

Spontaneous dyskinesia and Parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up

13.06.2002

Minor Physical Anomalies and Quantitative Measures of the Head and Face in Patients With Psychosis

13.06.2002

A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia

28.07.2000

Medical decision making in antipsychotic drug choice for schizophrenia